Last reviewed · How we verify
NovoRapid® Penfill®
NovoRapid is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells.
NovoRapid is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | NovoRapid® Penfill® |
|---|---|
| Also known as | insulin aspart, Insulin aspart |
| Sponsor | Geropharm |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
NovoRapid (insulin aspart) is a recombinant human insulin analog with a rapid onset of action, typically beginning to work within 10-20 minutes of injection. It mimics the body's natural insulin response to meals by binding to insulin receptors on muscle and fat cells, promoting glucose uptake and storage while inhibiting hepatic glucose production. This rapid action makes it suitable for mealtime insulin therapy in diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- China Research of IDEgAsp Treatment in Real-world Clinical practicE (CREATE)
- Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients (PHASE3)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Aspart to NovoRapid® Penfill® in Healthy Subjects (NA)
- A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects (NA)
- Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial (PHASE4)
- A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)
- Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (PHASE4)
- Surveillance Study of NovoRapid® for New Drug Re-examination
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NovoRapid® Penfill® CI brief — competitive landscape report
- NovoRapid® Penfill® updates RSS · CI watch RSS
- Geropharm portfolio CI